Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $31.00 Price Target at UBS Group

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its target price dropped by research analysts at UBS Group from $33.00 to $31.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group‘s price objective suggests a potential upside of 242.92% from the stock’s previous close.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. decreased their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Weiss Ratings raised Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. HC Wainwright reduced their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Finally, Mizuho set a $43.00 price objective on Syndax Pharmaceuticals in a research note on Tuesday, November 3rd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.40.

Get Our Latest Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock traded down $0.09 on Friday, hitting $9.04. 888,200 shares of the company traded hands, compared to its average volume of 1,884,865. The company has a debt-to-equity ratio of 38.95, a quick ratio of 4.37 and a current ratio of 4.69. The stock has a market capitalization of $813.85 million, a P/E ratio of -3.83 and a beta of 0.48. The business has a 50-day simple moving average of $14.41 and a 200 day simple moving average of $19.50. Syndax Pharmaceuticals has a 52 week low of $8.41 and a 52 week high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $83.30 million for the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The business’s revenue for the quarter was up 81.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Research analysts expect that Syndax Pharmaceuticals will post -2.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of Syndax Pharmaceuticals stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the transaction, the director directly owned 239,763 shares of the company’s stock, valued at $3,407,032.23. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.80% of the stock is owned by company insiders.

Institutional Trading of Syndax Pharmaceuticals

Large investors have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $26,000. Sterling Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 846.6% in the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after buying an additional 2,650 shares during the period. Nykredit A S purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $72,000. Integrated Wealth Concepts LLC bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $73,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Syndax Pharmaceuticals during the third quarter valued at $86,000.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Further Reading

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.